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From institutionalization to vocational independence
• Schizophrenia A Brain 
Disease
• ‘Mindless Brain’
• ‘Brainless Mind’
• Cognitive Theories; 
theories of Organization
• Cognitive Behavior 
Therapy in Schizophrenia
• Neuroimaging Correlates of 
Neuropychological Deficits
Processing external 
stimuli , executive 
memory and cognition.
Progress in Cognition and cognitive neuro-
sciences of schizophrenia
• Why are we talking so much about 
Cognition now a days. 
• 85% prevalence of cognitive symptoms, while 
Delusions and hallucinations are seen in only 40%
•  Fact that these are fairly stable, &
•  Correlation to Outcome 
Cognition as an outcome measure in schizophrenia
Kraepelin : adopted the term 
dementia praecox for a 
condition characterized by 
early psychosis and cognitive 
deterioration
 Bluer though 
emphasized on 
disconnection between 
affect, thought and 
perception, still viewed 
cognitive deficit as 
integral to disorder
The perceived importance of 
Cognition  in schizophrenia has 
since waxed and waned
Kraepelin’s Cognitive and 
negative symptoms were 
overshadowed by positive 
symptoms
RDC DSM iii & iv all 
emphasized on PS and 
Cognition is still not 
included in criteria
Research in schizophrenia is at a stage where in it has been irrefutably demonstrated 
by a host of workers that the 
key factor for social deficit, impairment, dysfunction and disability in 
schizophrenia is the problem particularly associated with cognitive set and 
consequences of neurodvelopmental process. 
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• 10% of all patients with schizophrenia work full 
time
• Only 1/3 ever work part time
• Fewer than 10% of male patients have a child
• Self care deficit is reflected in high rates of medical 
morbidity
Outcome Status
A renewed interest in cognition was seen recently, spurred by 
strong empirical relationship between cognition and real world 
functioning
Functional Outcome Since 1895
• ‘Several studies have failed to demonstrate positive correlation 
between positive symptoms and functioning’
• Change In QLS Total Score With Change in Memory Function - 
Positive Linear Correlation; Buchanan RW et al Biol.Psychiatry 
1994;36
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Impaired Cognition as a Core feature of 
schizophrenia and Cognitive symptoms lack 
Correlation with Positive symptoms and severity, 
suggesting its independence
• Individual reports that cognitive decline exists in 
schizophrenia started appearing early 1980; first 
was in 1977 by Cohen et al 
• The largest meta analysis for schizophrenia till date 
by Heinrichs and zakzanis 1998 established a 
performance lower by 0.46 to 1.46 SD 
• Explanation --- non disease factor, EPS, 
Medication etc.
• All  these were done on chronic patients , severely 
de-compensated, institutionalized... reports were 
not taken seriously.
Magnitude of Cognitive Deficits in Schizophrenia
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IS there a deficit, if so how much?
Large number of studies consistently indicated benefit of Cognitive enhancement to 
outcome and continue to raise our expectation
1994-Saykin et al, Philadelphia, Archives  - the first 
reliable report for neuropsychological deficit in 
neuroleptic naive first episode patients
1996 Meltzer wrote about ‘cognition schizophrenia and 
atypical antipsychotics’
By 1998  a correlation was established by imaging 
studies between cognitive decline, N-P Dysfunction, 
behavioral measures and neuroanatomical changes
 
by 2000/2001 concept of cognitive dysfunction and its 
contents was fairly established and various thought 
disorders seen in schizophrenia were explained by this 
theory like: cognitive neuropsychiatric model of 
persecutory delusions by Backwood et al 2001 AJP
Prevalence: how many patients show this 
deficit
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Where is the lesion and what is the deficiency
• 2002 hippocampal deformities in schizophrenia 
characterized by high dimensional brain mapping 
AJP Csernansky et al
• 2003 Neuronal correlates of episodic encoding and 
recognition of words in unmedicated patients 
during acute episode . Hofer et al, AJP 
• 2003 Diagnostic specificity and neuroanatomical 
validity of neurological abnormality in first episode 
psychosis
• Memory and executive function
• It has been further demonstrated that this cognitive change (dys-function 
or deficit) is the one which settles not only in early course of 
pathogenesis in adolescence and early adulthood, but may have  
originated during the prodromal phase of the illness in the individuals 
who are at-risk.
Chronic, deteriorating
Episodic, w/interepisode
 deficits ( common)
Episodic, w/o interepisode
 deficits
The course of schizophrenia 
Broad therapeutic window for
Prevention/Early intervention
• Impaired Cognition is not an epiphenomenon of clinical 
symptoms.
• Some studies have reported normal cognition in a 
significant number of people.
• 80-90% of twins with schizophrenia scored below their 
unaffected twins on N-P tests.
• 98% of people with schizophrenia performed below the 
level predicted by estimates of their premorbid functioning
• Several Studies have now demonstrated that Cognitive 
deficits occur in first episode of schizophrenia patients 
who have never taken antipsychotics.
Unlike Schneider’s first rank Symptoms 
Cognitive symptoms Correlate highly with 
measures of functional outcome
Overwhelming evidence of cognitive deficit has spurred
USA NIMH to target such deficits by pharmacological 
interventions (MATRICS)
Separate domain of deficit Vs generalized deficit
This debate has implication for etiology:
Whether the underlying brain abnormalities are
 local or global?
Antipsychotics and Cognitive 
Enhancement
Schizophrenia
Conventional 
APD 
Diminish 
Cognition
Conventional APD
Do not enhance 
cognition
Atypical brought 
the euphoria of 
enhancement
Latest Data:
gain from atypical 
are marginal. For 
enhancement
we need to look 
somewhere else
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A meta-analysis of 46 recent studies for N-P Change to clozapine, 
olanzapine, quetiapine, and Risperidone in schizophrenia; 
Woodward et al, Int J Neuropsychopharm.2005
Effect Sizes
• CONCLUSION: Adjunctive 
treatment with risperidone for 
6 weeks in patients with 
schizophrenia who had 
received chronic treatment 
with clozapine does not 
significantly improve 
cognitive function.
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1985, Historical Clozapine Studies started  bringing 
in the concept ‘reversibility’ of Cognition by 
H.Y.Meltzer et all and other groups.
Progress in NeuroCognition
• 2006  DB study of 
combination of 
clozapine with 
risperidone....: 
effects on 
cognition...J Cl. 
Psychiatry, Dec. 
2006
Cognitive status and employment in 
schizophrenia
California Verbal Learning Test
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Cognitive predictors of change
 in employment at 12 Month - 
clozapine study
Predictive Validity 
Cognitive Change and Symptom Correlations 
• Symptoms e.g. thought disorder* & insight*
• Only negative symptoms***
• Global symptoms
• Duration of untreated psychosis***
• Severity dimension
• Chronicity dimension
• Demography
Correlations were established by sophisticated imaging, observing: neuronal loss, recovery, 
anatomical positions and functional pathways, 
establishing direct link between ‘brain-lesions’ and functional outcome, providing valid 
arguments to look into the brain more and more by pharmacological probes
Symptoms & Cognition as
predictors of Community
Functioning
Symptoms after optimal treatment  are better predictors
as compared to Symptoms during acute episode
Symptoms ( disorganisation < psychomotor < < reality
distortion ) were more predictive than neurocognition
Ross Norman,Ashok Malla, AJP ,1999
Some doubts were also raised.
Cognitive deficit and 
functional outcome 
Effect Sizes (Cohen’s r) Strength of Relationship
Results from four different Mata-analysis
• Significant 
improvement in 
cognitive function 
• Better work performance
• Better social function
• Better social skills
• Better coping with stress 
• Hope!
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Large
Medium
Small
• Cognitive enhancement 
at different illness 
phases 
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Cognitive enhancement at different 
illness phases Three different trials
J Cl. Psychiatry. 2006 OCT.
• Comparison of Conventional and 
atypical antipsychotics effect on 
cognition- three different trials
Cognitive Enhancement
• The Evidence of Reversibility 
Olanzapine better than Haloperidol
 DB  trial  in the treatment of primary negative 
symptom and neurocognitive deficits in schizophrenia   
- JCP , J.P.Lindenmayer, 2007, March
Global Cognitive Index
Declarative VLM 
Attention Speed
Executive functioning
Simple Motor Functioning
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P-value for Difference between treatments• Neuropsychological results: 
significant differences in 
change from baseline to end 
point for the olanzapine-
treated group were seen for 
• A} declarative verbal learning 
memory ( F= 11.499, df=1,14; 
p= 0.021 ) &
•  B} Motor functioning 
domain ( F= 4.405, df=1,31; 
p= .044).
The First Episode:
 the paradox and the new hope
• 90% of FEP experience remission at the end 
of one year of treatment
• At 5 years follow up 80% had a job
• 80% had a relapse, of that 80% most had 
second relapse
• Predictors of outcome do not correlate with 
psychotic/remitted status
Recent Studies
• RSP V QP, NS 6,12 wk EUrAch.Psych l Ns, July 
07   QP better Reidel 
• OLN v QP Acute 4, 8 wk  JCP    july 07 QP better
• Keefe Study   July 07  OLN.RSP.QP
• CATIE
• OLn V. HP, Lindermayer JCP march 07 OL better
• CLP+RSP Meltzer , No benefit JCP dec 2006
• QP v RSP Harvey  8 Wks AJP nov 06, both good
• ZP v OLN Harvey 2003 
Strategies
1.Cognitive Enhancement
2. Cognitive Preservation
• Attempts were started to deal early and earliest  and 
address more investigation.
• ‘Early Intervention and Prevention of Schizophrenia’
• Non-pharmacological and Pharmacological methods 
were employed to enhance cognition
• CBT, Cognitive Remediation Therapy
• Several molecules
Cognitive re-mediation therapy (CRT) for young early onset 
patients with schizophrenia: an exploratory randomized 
controlled trial................Schizophrenia Research August 2007
The course of neurocognition and social 
functioning in individuals at ultra high risk for 
psychosis
Schizophrenia Bulletin August 2007
• UHR subjects showed significant cognitive deficits at baseline and 2 distinct 
profiles of cognitive change over time. 
• On average, 50% demonstrated improvement in social and role functioning 
over the follow-up period, while the other half showed either stability or 
decline in functioning.
•  Functional improvement was associated with improved processing speed 
and visual memory, as well as improvement in clinical symptoms over the 
follow-up period. 
• In contrast, patients who did not improve functionally showed stable clinical 
symptoms and cognitive performance over time.
The Ultra High Risk Individuals
Drugs- tried, tested, failed, & survived
to improve-  cognition-outcome-depression-NS, 
complex.
Every thing under the SUN
• Poly pharmacy 
• Many antipsychotics
• Antidepressant
• Mood stabilizers
• Conventional and 
atypical
• Psychotherapy
• Dopamine antagonists
• Dopamine agonists
• Serotonine blockers
• Alpha-adrenergics
• Cholinesterase inhibitors
• Herbal medicines
• Effect of donapezil added to atypical antipsychotics 
on Cognition in schizophrenia......World J. Biol. 
Psychiatry 
Conclusions: Adjunctive treatment with donepezil improves cognition in 
patients with schizophrenia who are stabilized on atypical antipsychotics
•  Despite the beneficial effects of atypical antipsychotics on cognition, many 
schizophrenic patients continue to suffer 
• Postmortem findings suggest that altered cholinergic activity is involved in 
cognitive impairment in schizophrenia. 
Experience with Adjunctive 
Rivastigmine and AAPD on Cognitive 
deficits - negative results
?
It was proposed that cognitive impairment: is 
a separate domain
• Cognitive symptoms correlate poorly with 
positive symptoms
• Cognitive symptoms are enduring whereas 
positive symptoms are phasic
• Improvement in cognition is independent of 
improvement in positive and negative 
symptoms and EPS in most but not all 
studies
Pharmacological and Non-pharmacological measures
• APD
• Cognition
• Functional outcome                    
• Social & Vocational outcome
Sequential 
Improvement
outcomecognition x
Model Building:
Neurocognition, Interventions, Mediators, and
Functional Outcome
• Social
• Occupational
• Independent 
  Living
• Rehabilitation 
  Success
Promising
Mediating
Variables
Neurocognitive
Capacities
Functional
Outcome
Domains
Interventions
Psychosocial
Psychopharmacological
Learning
Potential
Social 
Cognition
Other
Factors
Clinical
Symptoms
Volition
Environmental
Green, Meltzer, Newcomer & Bellack, APA 2000
Tools for measuring cognition: Depends upon the 
research questions
1.Neuropsych.Batteries, manual or Computerized
2.Psycho-physiological Tests
• Validity
• Time required
• Domain speficity
• Correlation with fuctional 
outcomes
• Statistical convertibility
• Culture neutrality 
• CATIE battery
• MATRICS battery
• BCA
• BACS
• RBANS,WAIR-
III,WMS,VCST
• UPSA, MCCB
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• CATIE  ...Study Highlights
 • The study was completed at 57 US centers. 18-65, 
Schizophrenia  
 • Randomized to receive olanzapine, quetiapine, 
risperidone, ziprasidone, or perphenazine. Dosing - 
flexible and based on clinicians' judgment. 
Participants and assesors were blind.
 • Neurocognitive testing was performed using 11 
different tests. Testing was completed at baseline and 
then at 2, 6, and 18 months of study treatment
The primary study outcome was the change in cognition 
from baseline to 2 months in each treatment group
Highly 
Complex 
statistical 
methods 
have been 
developed.
Results are 
being 
analysed 
and re-
analysed, 
as never 
before
• Improvement from base
• No significant inter-group 
differences
• Perphenazine as good as 
other atypical.
• When group with TD 
added, improvements 
sustained
• Patients with TD had less 
over all improvement
• Ziprasidone showed less 
improvement when TD 
group was excluded
0
0.075
0.150
0.225
0.300
LSM Improvement in Neurocognition
Olanzapine, p<.002
Perphenazine, p<.001
Quetiapine, p<.001
Risperidone, p<.001
Ziprasidone,p<.001
• Current status - CATIE Trial
2 Months, N=467 without TD
• Current status-CATIE Trial, 2 Months, 
individual NC domains across treatments
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• No significant disparity between the groups in improvement across the 
individual NC domains
• Change in the individual measures were small but consistently positive
Olanzapine
Perphenazine
Quetiapine
Rsperidone
Ziprasidone (Data set 3)
• Current status, CATIE Trial , at 6 Months, 
N= 523
• The NC composite score improved             
(p <0.001) for each of the treatment groups 
from base to 6 months
• There was no difference between the 
groups on the change in the NC 
composite score (p=0.35), or  any of the 
NC domains (all p values < 0.01)
• Current status - CATIE Trial, at 18 Months, 
N=303
• 37% patients were from 2 
months analysis
• 21% of  original pool
• Sample was found 
representative of entire pool on 
NC domains, 
• the improvement in composite 
score from month 2 to month 18 
was 0.11, suggesting that most 
of the cognitive improvement 
occurred in first 2 months of 
treatment
• Perphenazine group had better 
improvement than Olanzapine 
group or Risperidone group
• Ziprasidone and Quetiapine 
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• Current status: Keefe  Study, AJP 2007 July
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The relationships between change in cognition and 
change in social and vocational outcome??
•  Unaffected siblings show 
premorbid cognitive decline
• The team concludes: “To our knowledge, 
this is the first study demonstrating that 
unaffected siblings of people with familial 
schizophrenia have poor academic 
functioning during adolescence and 
deterioration in academic performance 
between childhood and adolescence 
compared with controls.
• Familial liability to schizophrenia and 
premorbid adjustment  British  J Psychiatry 
2007; 191: 260–261
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• Pooled across treatments, the partial correlations (controlling for baseline cognition and 
clinical symptoms) were small (0.14 and 0.18, respectively) at 12 weeks and roughly 
medium (0.22 and 0.36, respectively) at 52 weeks
• Associations are relatively small -- for two reasons
There were small differences 
between groups
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• One is that we do not have a clear pre-cognitive treatment effect in this study. 
• Second,  there is no psychosocial treatment component as part of this design that would facilitate translation 
of any cognitive benefits to the level of community functioning
Week 52
Enhancement basically occurs at
 2 months and sustains at 52 months
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CATIE Score and 
Functional outcome
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Quetiapine’s superiority at week 12 also is not very robust and it does not 
sustain up to week 52 . 
The discussion and explaination  is lacking on this point. 
• The explanation for superiority of quetiapine based upon blocking of 
muscarinic receptor by quetiapine is insufficient as there is a complex 
biological process for cognition. 
Conclusion - that we should not plan to address our 
unmet need for cognition enhancement with 
antipsychotic medications 
• The improvements seen with the second-generation 
medications are within the range of expectation. 
For this reason,
•  It is not known whether all three drugs have 
modest beneficial effects on cognition or whether 
they are all cognitively neutral
• The cognitive effects - 52 weeks were not 
significant, because of a slight reduction in effect 
size and reduced statistical power from attrition. 
• We need to look elsewhere
Cognition, Drug Treatment, and Functional 
Outcome in Schizophrenia: A Tale of Two 
Transitions 
Michael F Green.  The American Journal of 
Psychiatry.  Washington:Jul 2007.  Vol. 164,  Issue. 
• Optimism that second-generation antipsychotics 
would yield cognitive improvements has 
progressively been tempered as treatment effect 
sizes have progressively dwindled, possibly as a 
result of dosing factors (as doses of comparators 
became lower) or patient selection factors (as more 
patients received second-generation medications)
2. Atypical neuroleptics stimulate neurogenesis 
in adult rat brain
Wakade & Mahadik . Journal Neuroscience Res. 
• 1.Unlike conventional 
antipsychotics 
atypicals have been 
shown to be 
neuroprotective i.e.,
atypicals can prevent brain 
tissue loss associated with 
psychosis and stimulate 
neurite extension, 
neurogenesis, and cell 
survival 0
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3. Nerve growth factor (NGF) in 
Plasma schizophrenia subjects; 
Schizophrenia Bull. 2003
**
** *
How to Explain cognitive  enhancement by atypicals
Functional neuro-anatomy of cognitive deficits 
in schizophrenia - temporal lobe model
• Temporal Sagital Gyres (TSG)
• Dorsolateral Pre-frontal Cortex
• Hippocampal Formation (LTM)
• Corpus Callosum
DLPFC
Studies of Cognitive activation and fMRI Studies of working 
memory and cognitive controls Reveal
New treatments for cognition in 
schizophrenia
• Muscarnic antagonist: N-desmethyl clozapine
• Glutamate enhancers: Org 24448, LY 451 395
• GABA-A partial agonist: NGD 97-1
• Histamine antagonist : BF2-649
• Adrenergic modulators : c105
• 5-HT-1A antagonists : AV 965
• Nicotine partial agonist : Tc -1734
• Nk-3 antagonist : Sr 42801
The concept of neuronal plasticity and 
conditioning for memory 
The Nobel Prize in 
Physiology or 
Medicine 2000
Arvid Carlsson, Paul 
Greengard and Eric 
Kandel
for their discoveries 
concerning
 "signal transduction 
in the nervous 
system"
• Future Direction, New Molecules or New Genes??
COMT val108/158met genotype, cognitive function, and cognitive improvement with 
clozapine in schizophrenia...Schizophrenia Research, 2007 Feb
Genes:
multiple
susceptibility
alleles each of
small effect
Cells:
subtle
molecular
abnormalities
Systems:
abnormal
information
processing
psychiatric illness
Behavior:
complex functional
interactions and
emergent
phenomena
The path from here to there…
The Wisconsin Card Sorting Task
temperament
cognition
The COMT Gene 

• Cognition is integral to schizophrenia
• A criteria in DSM/ICD expected
• Deficits are related to global & social functioning, 
and can enhance outcome
• Measurement batteries would be simple and 
reliable
• Amongst various enhancing measures newer 
pharmacological molecules are expected
• Hope that practice of such therapy would be simple 
and cost-effective
• Hope that this would make a difference to life of 
patients
CONCLUSION:
Text
